May 29,2020 | Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against Sawai and Nichi-Iko | News | CHUGAI PHARMACEUTICAL CO., LTD.

Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit with the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule), against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd., the marketing authorization holders of generic versions of the drug, citing such parties’ infringement of a use patent owned by Chugai and Taisho Pharmaceutical Co., Ltd.

  1. Date of Complaint
    May 29, 2020
  2. Reasons for the Action
    On February 17, 2020, Sawai and Nichi-Iko received approval from the Ministry of Health, Labour and Welfare for their generic drugs of Edirol Capsule, respectively. Chugai and Taisho currently co-market Edirol Capsule wherein Chugai alleged that the generic drugs of Edirol Capsule infringe both companies’ use patent (patent number 5969161) , and filed an injunction with the Tokyo District Court against the manufacture, transfer, import, and offer of any transfer regarding the generic drugs, and disposal of stock.
  3. Defendants
    1. Name: Sawai Pharmaceutical Co., Ltd.
      Address: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
    2. Name: Nichi-Iko Pharmaceutical Co., Ltd.
      Address: 1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan
  4. Prospects
    No changes are expected to Chugai’s financial prospects at this point.

More:  Mar 31,2020 | Chugai Files for FoundationOne Liquid CDx Aiming to Provide Blood-based Comprehensive Genomic Profiling for Solid Tumors | News | CHUGAI PHARMACEUTICAL CO., LTD.

More from: | Category: Pharmaceutical Company News